Enanta Q1 net loss narrows to $22.3M; RSV Phase 2 topline data due Q3 2025

ENANTA PHARMACEUTICALS INC

2024-Q1 EPS reported -$1.05 revenue$16,959,000

Net loss $22.3M (-$1.05/sh) vs loss $33.4M (-$1.58/sh) YoY; revenue $17M from MAVYRET royalties.
Cash & securities $216.7M; expects runway into FY2028.
RSV zelicapavir Phase 2 RSVHR top-line data expected Q3 2025; Dec 2024 pediatric study showed antiviral effect.
Immunology: EPS-1421 KIT inhibitor IND studies ongoing; STAT6 candidate selection H2 2025; third program announced 2025.
Filed appeal in patent lawsuit against Pfizer over Paxlovid (Feb 3, 2025).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.